作者
Hooman Kamel, WT Longstreth Jr, David L Tirschwell, Richard A Kronmal, Joseph P Broderick, Yuko Y Palesch, Caitlyn Meinzer, Catherine Dillon, Irene Ewing, Judith A Spilker, Marco R Di Tullio, Eldad A Hod, Elsayed Z Soliman, Seemant Chaturvedi, Claudia S Moy, Scott Janis, Mitchell SV Elkind
发表日期
2019/2
期刊
International Journal of Stroke
卷号
14
期号
2
页码范围
207-214
出版商
SAGE Publications
简介
Rationale
Recent data suggest that a thrombogenic atrial substrate can cause stroke in the absence of atrial fibrillation. Such an atrial cardiopathy may explain some proportion of cryptogenic strokes.
Aims
The aim of the ARCADIA trial is to test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy.
Sample size estimate
1100 participants.
Methods and design
Biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial conducted at 120 U.S. centers participating in NIH StrokeNet.
Population studied
Patients ≥ 45 years of age with embolic stroke of undetermined source and evidence of atrial cardiopathy, defined as ≥ 1 of the following markers: P-wave terminal force >5000 µV × ms in ECG lead V1, serum NT-proBNP > 250 pg/mL, and left atrial diameter index ≥ 3 cm/m2 on …
学术搜索中的文章
H Kamel, WT Longstreth Jr, DL Tirschwell, RA Kronmal… - International Journal of Stroke, 2019